Subscribe for the newsletter
Sign in
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Directory
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
KEYTRUDA
Sort By
Newest First
1 / 1
FDA Approval
FDA Approved Keytruda for Kidney Cancer Sooner than Expected
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-M05-19-NI-001
May 02, 2019
Merck & Co.
Trial Update
Merck Provides Update on Phase 3 KEYNOTE-062 Trial
Merck & Co.
PR-M04-19-NI-085
Apr 29, 2019
Accelerated Approval
Merck’s Keytruda to Get Accelerated FDA Evaluation for Treatment of Head and Neck Cancer
Pharma's Almanac
PAO-M02-19-NI-015
Feb 19, 2019
Oncology
Positive Results for Keytruda as a Kidney Cancer Treatment
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-M10-18-NI-028
Oct 29, 2018
OncoSec Immunotherapies
Clinical Trials
OncoSec Initiates KEYNOTE-890, a Phase 2 Clinical Trial of TAVO in Combination with Merck's KEYTRUDA®
OncoSec Immunotherapies
PR-M10-18-NI-053
Oct 16, 2018
Oncology
EU Gives Nod to KEYTRUDA and Chemotherapy Combination Treatment
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-M09-18-NI-009
Sep 14, 2018
Merck & Co.
EMA
European Medicines Agency Adopts Positive Opinion for KEYTRUDA®(pembrolizumab) Combination with Pemetrexed and Platinum Chemotherapy
Merck & Co.
PR-M08-18-NI-009
Aug 02, 2018
Merck & Co.
Therapy Approval
KEYTRUDA® (pembrolizumab) is the First Anti-PD-1 Therapy Approved in China for Advanced Melanoma
Merck & Co.
PR-M07-18-NI-098
Jul 30, 2018
Merck & Co.
Phase III Trial
KEYTRUDA® (pembrolizumab) Monotherapy Met a Primary Endpoint in the Phase 3 KEYNOTE-048 Trial
Merck & Co.
PR-M07-18-NI-093
Jul 27, 2018
Merck & Co.
Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival and Progression-Free Survival for Squamous Non-Small Cell Lung Cancer (NSCLC)
Merck & Co.
PR-M05-18-NI-097
May 25, 2018
Merck & Co.
Oncology
Merck’s KEYTRUDA® (pembrolizumab) Reduced the Risk of Disease Recurrence or Death by More than 40 Percent
Merck & Co.
PR-M04-18-NI-63
Apr 18, 2018
Merck & Co.
Oncology
Merck's KEYTRUDA(R) (pembrolizumab) Significantly Improved Overall Survival and Progression-Free Survival as First-Line Treatment
Merck & Co.
PR-M01-18-NI-063
Jan 22, 2018
Eisai
Breakthrough Therapy
Eisai and Merck Receive Breakthrough Therapy Designation from FDA for LENVIMA® (lenvatinib mesylate) and KEYTRUDA® (pembrolizumab) as Combination Therapy
Eisai
PR-M01-18-NI-032
Jan 12, 2018
1 / 1
